Di Zhao1, Eliseo Guallar1, Pamela Ouyang2, Vinita Subramanya2, Dhananjay Vaidya3, Chiadi E Ndumele4, Joao A Lima2, Matthew A Allison5, Sanjiv J Shah6, Alain G Bertoni7, Matthew J Budoff8, Wendy S Post4, Erin D Michos9. 1. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. 2. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Division of Preventive Medicine, University of California-San Diego, La Jolla, California. 6. Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 7. Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina. 8. Los Angeles Biomedical Research Center at Harbor-UCLA, Torrance, California. 9. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: edonnell@jhmi.edu.
Abstract
BACKGROUND: Higher androgen and lower estrogen levels are associated with cardiovascular disease (CVD) risk factors in women. However, studies on sex hormones and incident CVD events in women have yielded conflicting results. OBJECTIVES: The authors assessed the associations of sex hormone levels with incident CVD, coronary heart disease (CHD), and heart failure (HF) events among women without CVD at baseline. METHODS: The authors studied 2,834 post-menopausal women participating in the MESA (Multi-Ethnic Study of Atherosclerosis) with testosterone, estradiol, dehydroepiandrosterone, and sex hormone binding globulin (SHBG) levels measured at baseline (2000 to 2002). They used Cox hazard models to evaluate associations of sex hormones with each outcome, adjusting for demographics, CVD risk factors, and hormone therapy use. RESULTS: The mean age was 64.9 ± 8.9 years. During 12.1 years of follow-up, 283 CVD, 171 CHD, and 103 HF incident events occurred. In multivariable-adjusted models, the hazard ratio (95% confidence interval [CI]) associated with 1 SD greater log-transformed sex hormone level for the respective outcomes of CVD, CHD, and HF were as follows: total testosterone: 1.14 (95% CI: 1.01 to 1.29), 1.20 (95% CI: 1.03 to 1.40), 1.09 (95% CI: 0.90 to 1.34); estradiol: 0.94 (95% CI: 0.80 to 1.11), 0.77 (95% CI: 0.63 to 0.95), 0.78 (95% CI: 0.60 to 1.02); and testosterone/estradiol ratio: 1.19 (95% CI: 1.02 to 1.40), 1.45 (95% CI: 1.19 to 1.78), 1.31 (95% CI: 1.01 to 1.70). Dehydroepiandrosterone and SHBG levels were not associated with these outcomes. CONCLUSIONS: Among post-menopausal women, a higher testosterone/estradiol ratio was associated with an elevated risk for incident CVD, CHD, and HF events, higher levels of testosterone associated with increased CVD and CHD, whereas higher estradiol levels were associated with a lower CHD risk. Sex hormone levels after menopause are associated with women's increased CVD risk later in life.
BACKGROUND: Higher androgen and lower estrogen levels are associated with cardiovascular disease (CVD) risk factors in women. However, studies on sex hormones and incident CVD events in women have yielded conflicting results. OBJECTIVES: The authors assessed the associations of sex hormone levels with incident CVD, coronary heart disease (CHD), and heart failure (HF) events among women without CVD at baseline. METHODS: The authors studied 2,834 post-menopausal women participating in the MESA (Multi-Ethnic Study of Atherosclerosis) with testosterone, estradiol, dehydroepiandrosterone, and sex hormone binding globulin (SHBG) levels measured at baseline (2000 to 2002). They used Cox hazard models to evaluate associations of sex hormones with each outcome, adjusting for demographics, CVD risk factors, and hormone therapy use. RESULTS: The mean age was 64.9 ± 8.9 years. During 12.1 years of follow-up, 283 CVD, 171 CHD, and 103 HF incident events occurred. In multivariable-adjusted models, the hazard ratio (95% confidence interval [CI]) associated with 1 SD greater log-transformed sex hormone level for the respective outcomes of CVD, CHD, and HF were as follows: total testosterone: 1.14 (95% CI: 1.01 to 1.29), 1.20 (95% CI: 1.03 to 1.40), 1.09 (95% CI: 0.90 to 1.34); estradiol: 0.94 (95% CI: 0.80 to 1.11), 0.77 (95% CI: 0.63 to 0.95), 0.78 (95% CI: 0.60 to 1.02); and testosterone/estradiol ratio: 1.19 (95% CI: 1.02 to 1.40), 1.45 (95% CI: 1.19 to 1.78), 1.31 (95% CI: 1.01 to 1.70). Dehydroepiandrosterone and SHBG levels were not associated with these outcomes. CONCLUSIONS: Among post-menopausal women, a higher testosterone/estradiol ratio was associated with an elevated risk for incident CVD, CHD, and HF events, higher levels of testosterone associated with increased CVD and CHD, whereas higher estradiol levels were associated with a lower CHD risk. Sex hormone levels after menopause are associated with women's increased CVD risk later in life.
Authors: Seamus P Whelton; Venkata Narla; Michael J Blaha; Khurram Nasir; Roger S Blumenthal; Nancy S Jenny; Mouaz H Al-Mallah; Erin D Michos Journal: Am J Cardiol Date: 2013-11-23 Impact factor: 2.778
Authors: Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick Journal: JAMA Date: 2007-04-04 Impact factor: 56.272
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Gotja Schaffrath; Hanna Kische; Stefan Gross; Henri Wallaschofski; Henry Völzke; Marcus Dörr; Matthias Nauck; Brian G Keevil; Georg Brabant; Robin Haring Journal: Maturitas Date: 2015-08-28 Impact factor: 4.342
Authors: Kathryn M Rexrode; JoAnn E Manson; I-Min Lee; Paul M Ridker; Patrick M Sluss; Nancy R Cook; Julie E Buring Journal: Circulation Date: 2003-09-15 Impact factor: 29.690
Authors: Lu Wang; Moyses Szklo; Aaron R Folsom; Nancy R Cook; Susan M Gapstur; Pamela Ouyang Journal: Atherosclerosis Date: 2012-07-20 Impact factor: 5.162
Authors: Lena Mathews; Vinita Subramanya; Di Zhao; Pamela Ouyang; Dhananjay Vaidya; Eliseo Guallar; Joseph Yeboah; David Herrington; Allison G Hays; Matthew J Budoff; Erin D Michos Journal: J Womens Health (Larchmt) Date: 2019-06-06 Impact factor: 2.681
Authors: Jie Hu; Jennifer H Lin; Monik C Jiménez; JoAnn E Manson; Susan E Hankinson; Kathryn M Rexrode Journal: Stroke Date: 2020-02-14 Impact factor: 7.914
Authors: Emily S Lau; Samantha M Paniagua; James Sawalla Guseh; Vijeta Bhambhani; Markella V Zanni; Paul Courchesne; Asya Lyass; Martin G Larson; Daniel Levy; Jennifer E Ho Journal: J Am Coll Cardiol Date: 2019-09-24 Impact factor: 24.094
Authors: Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Kavita Sharma; Sanjiv J Shah; Susan R Heckbert; Joao A Lima; Christopher R deFilippi; Matthew J Budoff; Wendy S Post; Erin D Michos Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958